Anti-Mouse CD31 (PECAM-1) [Clone 390] - FITC (C2464-GRP)

PECAM-1 was the first immunoreceptor tyrosine-based inhibition motif (ITIM)-containing receptor to be identified in platelets and acts as a negative regulator of platelet activation1. Platelet activation from a resting state has broad implications for many pathophysiological processes including anthogenesis, angiogenesis, inflammation, wound repair, and cancer metastasis. PECAM-1 inhibits platelet activation and thrombosis at sites of vascular injury by attenuating immunoreceptor tyrosine-based activation motif (ITAM)-containing receptor complex GPVI-FcR γ-chain signaling and by acting as a positive regulator of αIIbβ3-mediated outside-in signaling. PECAM-1, like all ITIM-containing receptors, belongs to the immunoglobulin receptor superfamily. PECAM-1 also functions as a cell adhesion molecule and is capable of mediating calcium- dependent heterophilic aggregation2. Additionally, PECAM-1 is expressed at cell-cell borders in the endocardial cells of the developing murine heart3. Because of its distribution pattern, PECAM-1 is a target molecule for the delivery of antithrombotic agents4,5,6,7. Research is being conducted into the ability of PECAM-1 to deliver drugs to the endothelium. Clone 390 was generated by immunizing rats with mouse 32D leukocyte cell line and screening against muPECAM-1Δ12,153,8. 390 binds to an epitope on Ig-domain 2 of muPECAM-17,9.